Overall , the method indicated no statistically significant overall treatment effect in favour of erlotinib ; if anything , the point estimate of the net proportion leaned in favour of the placebo group ( overall proportion in favour of erlotinib = -3.6 % , 95 % CI , -14.2 - 7.1 % ; P = 0.51 ) .